|Bid||7,000.00 x 0|
|Ask||7,640.00 x 0|
|Day's range||7,209.00 - 7,279.00|
|52-week range||109.51 - 8,227.88|
|Beta (3Y monthly)||0.20|
|PE ratio (TTM)||45.56|
|Earnings date||14 Feb 2020|
|Forward dividend & yield||2.19 (3.03%)|
|1y target est||78.83|
AstraZeneca today presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that CALQUENCE® (acalabrutinib) combined with obinutuzumab or as monotherapy significantly improved progression-free survival (PFS) compared to chlorambucil plus obinutuzumab, a standard chemo-immunotherapy treatment, in patients with previously untreated chronic lymphocytic leukemia (CLL).
When the going gets tough, dividends get cut. Given today's volatile market conditions, mature economic cycle, and historically high dividend yields that are o8230;
The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo. Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.
AstraZeneca Plc and Merck & Co Inc said on Thursday that their drug, Lynparza, won approval in China as a first line treatment for a form of ovarian cancer. The approval in China is based on the results from a late-stage study in which Lynparza lowered the risk of disease progression or death by 70% when compared to placebo. Lynparza is currently approved in 65 countries for the maintenance treatment of platinum-sensitive relapsed ovarian cancer, the companies said.
Some recent stock market successes for UK companies have resulted in over-inflated stock prices. I look at three worth watching in 2020.
China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement. Many branded versions of drugs are currently more expensive in China than in other major markets. The bulk-buy program, which currently covers 25 types of medicines, allows no more than three successful bidders access to China's public hospitals, where most Chinese people buy their drugs.
Attention FTSE 100 investors! This is a dividend stock worth buying now and holding for the next 10 years, says Royston Wild.
The company said the U.S. Food and Drug Administration (FDA) accepted its supplemental application and granted priority review to Imfinzi for the treatment of previously untreated late-stage small cell lung cancer (SCLC). The FDA decision is a boost for the treatment as it competes against similar medicines from rivals Merck and Roche , and follows data in September which showed Imfinzi prolonged survival in SCLC patients when used with chemotherapy.
AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukaemia drug, in a challenge to rival AbbVie . AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go ahead for the company's Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukaemia in adults. The drug was approved under a new speedy review programme in collaboration with drug watchdogs in Canada and Australia, and was also approved to treat small lymphocytic lymphoma, a similar disease.
AstraZeneca shares rose 2.7% on Friday after the British drugmaker won earlier-than-expected U.S. regulatory approval for a leukemia drug, in a challenge to rival AbbVie . AstraZeneca said late on Thursday that the U.S. Food and Drug Administration (FDA) had given its go ahead for the company's Calquence drug to treat chronic lymphocytic leukemia (CLL), one of the most common types of leukemia in adults.
London's FTSE 100 surged more than 1% on Friday after two days of selling, as investors turned cautiously optimistic about a Sino-U.S. trade deal and exporter stocks rose after the pound weakened on downbeat U.K. Purchasing Managers' Indexes (PMI) data. The FTSE 250 added 0.6%, though gains were capped by data that showed British business this month suffered its deepest downturn since mid-2016 amid uncertainty around the general election and Brexit. Further keeping gains in check was a 9% slide in Hochschild Mining after its 2020 output targets disappointed, and an 8% drop in thread manufacturer Coats Group after it warned on annual profit.
Britain's BT has told a company promoting digital skills it would continue working with it if it dropped Prince Andrew as a patron. The British royal has been engulfed in a growing scandal since he gave a TV interview on Saturday to discuss his friendship with Jeffrey Epstein, who killed himself in a U.S. prison in August while awaiting trial on sex trafficking charges. Andrew denied an allegation that he had sex with a 17-year-old girl procured for him by Epstein but said he did not regret the friendship.
A scheme for entrepreneurs founded by Prince Andrew has taken down the logos of its corporate sponsors from its website, as firms and charities distance themselves from the British royal over a sex scandal. Andrew, Queen Elizabeth's second son, denies an allegation that he had sex with a 17-year-old girl procured for him by his friend Jeffrey Epstein, who killed himself in a U.S. prison in August while awaiting trial on sex trafficking charges. The scandal has escalated since Andrew's rambling denials and explanations in a disastrous TV interview aired on Saturday left many viewers incredulous, and his apparent lack of compassion for Epstein's victims drew widespread condemnation.
Stockopedia’s own data points to a jarringly simple stock market truth amidst the daily whirlwind of financial data: share prices that have gone up tend to kee8230;
European stocks ended flat on Monday as a spurt of defensive buying over uncertainty surrounding U.S.-China trade talks helped temper losses in the auto sector. The pan-European STOXX 600 index finished little changed, after having spent most of the session in negative territory. The European automobiles and parts sector dropped 2.1%, its steepest fall in about four weeks, with Germany's Volkswagen leading declines after it slashed its operating profit and sales growth outlook due to slowdown in the auto sector.
UK mid-caps closed at their highest level in nearly 14 months on Monday, boosted by polls pointing to victory by the ruling Conservatives in upcoming elections, while a near 5% drop in insurer Aviva weighed on the main board. The domestically-focused FTSE 250 index rose 0.2% while the FTSE 100 added 0.1%.
London's main bourse retreated on Wednesday as traders grew weary of mixed trade signals from U.S. President Donald Trump, while mid-caps slid on the back of weak economic data and a plunge in Tullow Oil. The more internationally-exposed FTSE 100 fell 0.2%, trimming some early losses as exporter stocks such as Diageo and AstraZeneca benefited from a weaker pound. The jump in exporter shares also helped the bourse outperform the broader European benchmark index.